Panax ginseng panax ginseng sanqi American patent investigation

Time: 2018-04-10 source: China intellectual property report author: zhang hailong

Ginseng, panax ginseng and panax ginseng are important and valuable 3 kinds of Chinese medicinal herbs. In recent years, the chemical constituents and pharmacological activities of these three medicinal herbs have been developing rapidly. This article through to ginseng, American ginseng and notoginseng in the United States patent application number, patent holder, IPC category, and the latest U.S. patent application trends were analyzed, and strive to provide the newest trend of three kinds of Chinese herbal medicine in the United States patent application. The author analysis found that south Korean companies in ginseng, American ginseng, leading the United States patent ownership, and the applicant for a patent for cosmetics companies as the main, and Chinese companies notoginseng medicinal materials in a leading position in the United States patent ownership, and the applicant is given priority to with pharmaceutical companies one more. In conclusion, the research and development level of ginseng and western ginseng is significantly better than that of sanqi, which will have great development potential in the future.

Patent analysis and layout of three medicinal herbs.

Ginseng, panax ginseng and 3, 73 traditional Chinese medicine sources are similar, chemical composition is similar, for example, 3 kinds of medicinal materials contain ginsenoside Re1, Rg1 component [1-3]. Ginseng for five plus families Panax ginseng plant ginseng C.A.M ey. The roots and rhizomes of dry, sex, sweet, bitter in taste and lukewarm, spleen, lung, heart, kidney, fill with vigour, the effect of double pulse solid take off, for the treatment of "body empty to take off, limb vein micro cold, eat less pixu (spleen deficient), lung deficiency asthmatic cough, thirst", tianjin. American ginseng for five plus families American ginseng plant Panax quinquefolium l. dry root, taste sweet, bitter, cool, for centering, lung, kidney, with tonifying qi, nourishing Yin, the effect of heat fluid, used in the treatment of "deficiency of Yin deficient, heat bother tired, cough and gasp the sputum blood, diabetes, dry mouth, dry throat". Notoginseng for five plus plants Panax notoginseng (Burk.) F.H.C hen of dry root and rhizome, taste sweet, bitter, warm, belong to the liver, stomach, have the effect of the scattered stasis stop bleeding, swelling and pain, for the treatment of hemoptysis, hematemesis, carp, trauma, bleeding, blood chest hurt and pain in the fall on ".

Ginseng, western ginseng, is one of the three widely used Chinese medicinal herbs. At present, the research on the three kinds of Chinese herbal medicine has made great progress, especially in the research of chemical composition and pharmacological activity. The United States patent in these three kinds of traditional Chinese medicine is the main high point of the industry competition. Through the analysis of American patent and layout, it can indirectly reflect the internationalization development degree of this technology research field.

Based on the patent retrieval of the us patent and trademark office (USPTO) database, the author analyzed the patent authorization status of ginseng, panax ginseng and sanqi in the United States from 1971 to 2017.

By analyzing, the author found that before 1995, American ginseng, American ginseng in patent grant below five parts, the first application for a patent for peak appeared in 2000 and 2002, after 2002 years in the field showed a trend of decline, in 2009 appeared the second active period. The author analyzes believed that ginseng, American ginseng after 1998 patent applications into the active period, show that the period of the technical conditions made of ginseng and American ginseng research and industrialization development direction more clearly. The total number of U.S. patent applications is relatively small, but the peak of the patent application is similar to ginseng and western ginseng, respectively in 2002 and 2008. Based on the analysis of patent application, the number of patent applications in the United States increased dramatically in the period of 2000, which was a period when ginseng, western ginseng and sanqi were active.

From ginseng, American ginseng, an application for a patent for the main body in the United States, now in many application subject, in the first post exchanges (PXS) across the company from South Korea, followed by Switzerland FX LIFE SCIENCES AG, was ranked the third is a Korean company. Among the top 10 companies, only one is from China, and is jilin zixin pharmaceutical. It can be seen that Korean companies are in a leading position in the research and development of ginseng and western ginseng, indicating that their r&d innovation has the international leading edge. From the perspective of the patent application subject of notoginseng in the United States, in the first place is tianjin tasly pharmaceutical co., LTD from China in second place is a Korean company, came in third place was the Access Business Group of companies in the United States. In the research and development field of 37, Chinese enterprises are in the leading position.

Through the analysis of the application for a patent for main body, it can be seen that in developed areas of ginseng, American ginseng, south Korean companies with strong advantages, in the field of research and development of notoginseng, China is in the lead. South Korea's main body of patent applications is cosmetics companies, while China's patent applications are dominated by pharmaceutical companies.

The patent classification and development of three medicinal herbs.

In addition to the above analysis, the author also analyzes based on IPC classification number, in an application for a patent for the ginseng, American ginseng, A61K36 class (usually involved in traditional Chinese medicine) occupy a larger proportion in the classification number, accounted for 25.2%, A61K31 (usually involves western medicine) occupy 8.4% in the major categories. Of the 37 U.S. patent applications, the A61K36 category accounted for 25% of the classification number, and the A61K31 category accounted for 7.8% of the major categories. It can be seen that ginseng, panax ginseng, and sanqi have a similar proportion in A61K36 and A61K31, indicating that ginseng and western participation in the study or application field are similar.

It is worth noting that in the A61P9 category, the proportion of us patent applications in the United States is 7.8%, which is significantly higher than that of ginseng and American ginseng. The A61P9 category is related to cardiovascular and cerebrovascular therapy, indicating that the r&d and industrialization of sanqi are closely related to the treatment of cardiovascular and cerebrovascular diseases. This is closely related to sanqi's blood stasis. Ginseng, American ginseng, American patent applications in the category of A61Q19 possess higher proportion, A61Q19 categories related to skin care and cosmetics, show that ginseng, American ginseng in the development of skin care products and cosmetics have good application prospect.

The author based on IPC classification, analysis, notoginseng patent occupy a higher proportion in A61P9 category, this reflects another aspect of notoginseng and ginseng, American ginseng the main difference in efficiency. The patent of ginseng and panax ginseng is widely used in the cosmetic field besides the traditional medicine field. Currently, the development of sanqi is mainly applied to traditional drug therapy, and it has not been developed in other fields.

Ginseng, panax ginseng and panax ginseng are the most important Chinese medicinal materials. Through the analysis of the American patent, we can see the competitive strength of the patent of enterprises in various countries, and the development trend of technology research and development in this field. To sum up, it can be seen that ginseng and western participation in the patent application activity period is similar, and the patent application of 37 is slightly later than ginseng and western ginseng. Chinese enterprises have strong advantages in the research and development field of sanqi. Both China and South Korea are major producers of ginseng, and Chinese companies have less U.S. patent ownership than south Korean companies. South Korea has a strong competitiveness in the industrialization of ginseng and western ginseng. In the field of cosmetics, Korean companies have integrated traditional herbal medicine with their national dominant industries and developed a series of cosmetics with ginseng characteristics. Although China is a major producer of ginseng, the development and application of ginseng is still in the traditional pharmaceutical research and development, and the diversified industrial chain related to ginseng and western ginseng has not yet been formed. The analysis of American patent application and patent layout can provide a new direction for Chinese enterprises in the development and application of ginseng, western ginseng and sanqi products.